Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Dec;12(6):4297-4300.
doi: 10.3892/ol.2016.5260. Epub 2016 Oct 13.

Stem cell transplantation during cancer

Xiao-Ying Zhang  1 , Pei-Ying Zhang  2
Affiliations

Stem cell transplantation during cancer

Xiao-Ying Zhang et al. Oncol Lett. 2016 Dec.

Retraction in

Abstract

Hematological malignancies account for approximately 9.5% of new cancers diagnosed annually. Lymphoma is the most frequent of all known categories of hematological malignancies. Worldwide, extensive research has focused on this type of cancer. However, new treatments are investigated in various clinical as well as pre-clinical studies. Hematopoietic stem cell transplantation (HSCT) is a recent and upcoming treatment strategy for patients with hematopoietic malignancies and inborn errors of metabolism or immune deficiencies. Recent studies have revealed that successful clinical outcome of this treatment strategy depends on multiple factors including the protocol applied, disease under treatment, health of the patient, source of the grafts, severity of complications such as graft versus host disease during grafting and associated infections. The scope of this review is to achieve greater understanding of various clinical effects of the disease and related mechanisms. The electronic database Pubmed was searched for pre-clinical as well as clinical controlled trials reporting efficacy of the HSCT against hematological malignancies.

Keywords: cancer; hematopoietic stem cell transplantation; mechanism; stem cell.

PubMed Disclaimer

Similar articles

See all similar articles

References

    1. Nakasu Y, Mitsuya K, Hayashi N, Okamura I, Mori K, Enami T, Tatara R, Nakasu S, Ikeda T. Response-adapted treatment with upfront high-dose chemotherapy followed by autologous stem-cell transplantation rescue or consolidation phase high-dose methotrexate for primary central nervous system lymphoma: a long-term mono-center study. Springerplus. 2016;5:307. doi: 10.1186/s40064-016-1954-6. - DOI - PMC - PubMed
    1. Szyska M, Na IK. Bone marrow GvHD after allogeneic hematopoietic stem cell transplantation. Front Immunol. 2016;7:118. doi: 10.3389/fimmu.2016.00118. - DOI - PMC - PubMed
    1. Bortin MM. A compendium of reported human bone marrow transplants. Transplantation. 1970;9:571–587. doi: 10.1097/00007890-197006000-00006. - DOI - PubMed
    1. Passweg JR, Baldomero H, Bader P, Bonini C, Cesaro S, Dreger P, Duarte RF, Dufour C, Falkenburg JH, Farge-Bancel D, et al. European Society for Blood and Marrow Transplantation (EBMT): Hematopoietic SCT in Europe 2013: recent trends in the use of alternative donors showing more haploidentical donors but fewer cord blood transplants. Bone Marrow Transplant. 2015;50:476–482. doi: 10.1038/bmt.2014.312. - DOI - PMC - PubMed
    1. Svahn BM, Remberger M, Myrback KE, Holmberg K, Eriksson B, Hentschke P, Aschan J, Barkholt L, Ringdén O. Home care during the pancytopenic phase after allogeneic hematopoietic stem cell transplantation is advantageous compared with hospital care. Blood. 2002;100:4317–4324. doi: 10.1182/blood-2002-03-0801. - DOI - PubMed

Publication types